Helix Acquisition Corp. II
Status: Live Deal
U=S
| IPO Proceeds, $M | $184.00M |
|---|---|
| IPO Date | Feb 9, 2024 |
| CEO | Bihua Chen |
| Left Lead | Leerink Partners |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector | Healthcare â–¶ |
| IPO Geography | US/Canada |
| Target Company | BridgeBio Oncology Therapeutics |
| Deal Announced | Feb 28, 2025 |
| Deal Size, $M | $360.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | TBD |
| Amendment Vote | TBD |
HLXB
| Price | $10.67 |
|---|---|
| Last closing price | $10.80 |
| H/L, today | $10.66 / $10.89 |
| Volume, today | 152,823 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.